Ex-Purdue Pharma chief Mark Timney, named in dozens of opioid lawsuits, nabs another biotech CEO gig
Facing hundreds of lawsuits over its role in fueling the US opioid epidemic, Purdue Pharma is in the midst of full-scale teardown — but that doesn’t mean its former leaders aren’t making off well. Coming off a stint driving RNAi therapy inclisiran to a buyout, former Purdue CEO Mark Timney has found a new home at the helm of a small biotech.
On Monday, Attralus Therapeutics announced Timney’s hire as CEO amid a flurry of additions to the biotech’s brain trust.
Unlock this article instantly by becoming a free subscriber.
You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.